(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2013 (11.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/052311 A1

(51) International Patent Classification:
A61K 38/18 (2006.01) *C07K 14/50* (2006.01)

(21) International Application Number:
PCT/US2012/057053

(22) International Filing Date:
25 September 2012 (25.09.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/542,906 4 October 2011 (04.10.2011) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: **DICKINSON, Craig, Duane**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **DRIVER, David, Albert**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **DARLING, Ryan, James**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **GONCIARZ, Malgorzata, Donata**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US). **MICANOVIC, Radmila**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(74) Agents: **CASTETTER, Andrea** et al.; Eli Lilly And Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/052311 A1

(54) Title: FIBROBLAST GROWTH FACTOR 21 VARIANTS

(57) Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.